Safety of FOLFIRI + Durvalumab +/- Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59
Evrard, Camille, Aparicio, Thomas, Soularue, Emilie, Le Malicot, Karine, Desramé, Jérôme, Botsen, Damien, El Hajbi, Farid, Gonzalez, Daniel, Lepage, Come, Bouché, Olivier, Tougeron, David, On Behalf Of The Durigast-Prodige Investigators/Collaborators
Published in Biomedicines (23.05.2022)
Published in Biomedicines (23.05.2022)
Get full text
Journal Article